What’s the current market cap for H. Lundbeck A/S stock?

H. Lundbeck A/S (HLUN B) has a market cap of DKr41bn as of June 17, 2026.

What is the P/E ratio for H. Lundbeck A/S stock?

The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUN B) stock is 11.22 as of June 17, 2026.

Does H. Lundbeck A/S stock pay dividends?

Yes, the H. Lundbeck A/S (HLUN B) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is DKr1.15 and the yield is 2.73%. H. Lundbeck A/S has a payout ratio of 30.59% on a trailing twelve-month basis.

When is the next H. Lundbeck A/S dividend payment date?

The next H. Lundbeck A/S (HLUN B) dividend payment date is unconfirmed.

What is the beta indicator for H. Lundbeck A/S?

H. Lundbeck A/S (HLUN B) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy H. Lundbeck A/S stock | DKrHLUN B Share Price

07:00

09:00

11:00

12:55

14:55

About H. Lundbeck A/S

H. Lundbeck A/S is a Danish pharmaceutical company specializing in the research, development, and marketing of products for the treatment of brain diseases. The company focuses on areas such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and has a significant global presence with facilities across Europe, North America, and Asia. Lundbeck's strategic positioning is underscored by its dedicated emphasis on central nervous system disorders, supported by a robust pipeline of research and development projects. The company places a strong emphasis on scientific and clinical excellence, aiming to deliver innovative therapies to improve patient outcomes.

Ticker

DKr HLUN B

Sector

Health

Primary listing

CSE

Employees

5,000

Headquarters

Valby, Denmark

Website

www.lundbeck.com

H. Lundbeck A/S Metrics

BasicAdvanced

kr 41bn

11.22

kr 3.76

0.26

kr 1.15

2.73%

Bulls say / Bears say

On May 12 2026, Lundbeck raised its 2026 revenue growth forecast to 7–9% and adjusted EBITDA growth to 8–14%, driven by robust U.S. demand for Vyepti and delayed generic competition for Abilify Maintena (Reuters).

In Q1 2026, Lundbeck delivered 21% constant-exchange revenue growth to DKK 7.13 billion and a 26% increase in EBITDA to DKK 2.63 billion, reflecting strong uptake of its strategic brands across all regions (Reuters).

Lundbeck secured marketing authorization for its migraine therapy Vyepti in South Korea, expanding its geographic footprint in the preventive migraine market amid strong Phase 3 data (Reuters).

Jefferies downgraded H. Lundbeck to “underperform” citing looming patent expiries on several key drugs, with about 60% of sales at risk and most new pipeline candidates unlikely to reach the market before 2028 to offset 2029 patent losses (Reuters).

Exane BNP Paribas initiated coverage at “neutral” warning of a long-term pipeline “headache,” forecasting 30% of peak strategic brand revenue lost by 2030 due to patent expiries and up to 75% by 2035 without material de-risking events until 2026–2027 (Reuters).

Lundbeck’s own 2025 corporate release warns of intensifying generic competition in 2026—particularly for aripiprazole LAI in Europe, Australia, and Canada—and structural declines in mature brands that may pressure revenue growth (Corporate Release).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy DKr HLUN B

DKr

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Lundbeck secured marketing authorization for its migraine therapy Vyepti in South Korea, expanding its geographic footprint in the preventive migraine market amid strong Phase 3 data (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About H. Lundbeck A/S

Ticker

Primary listing

Employees

Headquarters

H. Lundbeck A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy DKr HLUN B

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

H. Lundbeck A/S/DKr HLUN B

About H. Lundbeck A/S

Ticker

Primary listing

Employees

Headquarters

H. Lundbeck A/S Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy DKr HLUN B

Upcoming events

No upcoming events

What’s the current market cap for H. Lundbeck A/S stock?

What is the P/E ratio for H. Lundbeck A/S stock?

Does H. Lundbeck A/S stock pay dividends?

When is the next H. Lundbeck A/S dividend payment date?

What is the beta indicator for H. Lundbeck A/S?

Bulls say / Bears say